Axsome Therapeutics, Inc. research snapshot
AXSM AI stock analysis currently reads Axsome Therapeutics, Inc. as a commercial-stage central nervous system biopharma with fast Auvelity-led product growth, three marketed CNS medicines, an expanding late-stage pipeline, and material profitability and valuation risk. At the July 12, 2026 data cutoff, AXSM traded near $233.80 with a verified market capitalization of about $12.03 billion using 51.46 million shares. FY2025 total net product revenue reached $638.5 million, Q1 2026 revenue was $191.2 million, and the company was still GAAP loss-making. This page uses scenarios, technical levels, and source-backed facts. It is informational research, not investment advice.
Current price
$233.80
Market cap
$12.03 billion
AI score
61 / 100
Rating
High-growth commercial CNS biotech, still loss-making and valuation-sensitive
Trend status
Long-term uptrend intact, short-term neutral after pullback toward support
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Axsome sells CNS medicines led by Auvelity in major depressive disorder and Alzheimer disease agitation, plus Sunosi for excessive daytime sleepiness and Symbravo for acute migraine. | High |
| Moat | The moat comes from differentiated mechanisms, patents, labels, specialist and primary-care relationships, and commercial infrastructure. It is not a network-effect franchise and must be defended product by product. | Medium |
| Management | Founder-CEO Herriot Tabuteau has built a multi-product CNS portfolio and advanced Auvelity into a second indication, but capital allocation is still judged by the path to cash-flow positivity and pipeline ROI. | Medium-high |
| Financial trend | FY2025 total net product revenue rose to $638.5 million (+66% YoY), Q1 2026 revenue reached $191.2 million (+57% YoY), while FY2025 net loss was $183.2 million and Q1 2026 net loss was $64.5 million. | High |
| Valuation | At $233.80, AXSM traded near 18.8x FY2025 revenue and about 17.0x TTM revenue near $708 million, with trailing PE still negative at roughly -63.5x on FY2025 EPS of -$3.68. | Medium-high |
| Technical trend | ChartMill showed a long-term uptrend and short-term neutral setup, with price near $233.80, support around $232 to $234, secondary support near $216, and resistance near $255. | Medium |
| Risk level | Main risks are Auvelity concentration, Alzheimer agitation launch execution, SG&A intensity, continued losses, competitive CNS drugs, clinical or regulatory setbacks, dilution, and multiple compression. | Medium-high |
| AI confidence | High for descriptive research and calculations. Lower for exact price outcomes because biotech stocks reprice around launch metrics, trial data, FDA updates, and payer news. | High data confidence |
| Investment certainty | Medium-low certainty. Product growth is strong, but durable free cash flow and a justified premium multiple still depend on multi-year commercial and pipeline execution. | Medium-low |
AXSM AI stock forecast
The AXSM AI stock forecast uses scenario ranges around the $233.80 quote. Because FY2025 GAAP EPS was -$3.68, the mandatory three-scenario EPS tool produces non-economic negative targets and is not used as a price forecast. An illustrative path-to-profit framework using a $4.00 EPS base with bull, base, and bear growth and PE assumptions produced roughly $313, $149, and $51. Commercial and launch-driven ranges below are more decision-relevant for a still-loss-making CNS company.
$300 to $360
More likely if Auvelity keeps scaling in MDD, the Alzheimer agitation launch starts well after the June 2026 commercial push, Symbravo coverage and scripts accelerate, pipeline readouts such as solriamfetol and AXS-12 progress cleanly, and investors keep paying a premium growth multiple as losses narrow.
$180 to $250
More likely if product revenue keeps growing toward the roughly $1.0 billion 2026 analyst revenue area but SG&A and R&D keep AXSM loss-making, valuation compresses from current sales multiples, and the market waits for clearer cash-flow positivity.
$100 to $160
More likely if Auvelity growth slows, Alzheimer agitation uptake disappoints, payer pressure cuts net price, a material pipeline readout or regulatory event fails, cash burn forces dilutive financing, or the stock rerates toward a lower sales multiple.
AXSM AI technical analysis
AXSM AI technical analysis is mixed-to-constructive as of the July 12, 2026 cutoff. Public closes around July 10 to July 11 were near $233.80 after a pullback from the $260.19 area. ChartMill listed a long-term uptrend, short-term neutral trend, support from $232.02 to $233.79, secondary support near $216.47, resistance near $255.18, RSI near 44.22, and SMA(50)/SMA(200) near $234.47 and $176.66.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $233.80 | Recent public close used for July 12, 2026 research and market cap math with 51.46 million shares. |
| Near support | $232 to $234 | ChartMill listed a support zone from $232.02 to $233.79 formed by multiple trend references. |
| Secondary support | $216 to $217 | ChartMill listed horizontal support near $216.47, useful if the first support zone fails. |
| Deeper support | Near $171 | ChartMill listed a deeper daily trend-line support near $171.26 for a full trend-break review. |
| Moving averages | Mixed short term, constructive long term | ChartMill SMA(5)/SMA(20)/SMA(50)/SMA(200) were near $244.14, $245.76, $234.47, and $176.66. Price sat near the 50-day and well above the 200-day average. |
| Resistance | Near $255 | ChartMill listed resistance around $255.18. The recent range high and 52-week high area sits near $260.19. |
| Momentum | Cooling after a strong multi-month run | RSI near 44 and a slightly negative MACD signal a short-term cooldown inside a still-positive longer-term trend. |
| Volume | Event-sensitive biotech volume | Average volume near 1.0 million shares on ChartMill. Compare volume on earnings, Auvelity Alzheimer launch updates, FDA news, and pipeline readouts. |
| Volatility | High for a commercial-growth biotech | ATR around 4% and a 52-week range from $96.09 to $260.19 show large swings around commercial and clinical catalysts. |
| Invalidation | Close below $232, then $216 | A decisive close below the $232 support zone would weaken the swing setup. A break below $216 would require a deeper thesis review. |
AXSM AI trading strategy
The AXSM AI trading strategy is a rules-based framework for a high-growth CNS biotech with product concentration, launch risk, and event volatility. It is not personal advice and should be paired with live quotes, filings, position sizing, and clinical or commercial event checks.
Watch for AXSM to hold above the $232 to $234 support zone, reclaim the $244 to $246 short moving averages, and challenge the $255 to $260 resistance area with confirming volume and no negative launch or trial news.
A close below $232 should invalidate the short-term swing setup. A close below $216 should force a full review of Auvelity growth, Alzheimer agitation uptake, cash runway, and valuation assumptions.
If AXSM pulls back toward support without a new commercial, payer, or clinical problem, compare the price move with Q1 product growth, Auvelity prescription trends, Symbravo coverage gains, and cash burn.
Do not treat every pullback as mean reversion. Biotech support levels can fail fast when launch metrics, reimbursement, or trial news change the growth narrative.
Track Auvelity MDD and Alzheimer agitation sales, Sunosi prescriptions and royalties, Symbravo coverage and scripts, SG&A spend, R&D milestones for solriamfetol and AXS-12, cash of $305.1 million at March 31, 2026, and debt near $188 million.
Reduce confidence if valuation depends mainly on a premium sales multiple rather than durable net-price growth, controllable opex, and a credible path to cash-flow positivity.
Investment research summary
Axsome turns CNS science, regulatory approvals, and commercial execution into product revenue from medicines for depression, Alzheimer agitation, sleepiness disorders, and migraine. Customers and payers pay when efficacy, access, and tolerability beat alternatives for those conditions.
The moat is strongest where mechanism differentiation, labels, patents, payer coverage, and sales relationships reinforce each other. It narrows if generics, competing branded CNS drugs, or weaker net pricing erode growth in Auvelity, Sunosi, or Symbravo.
The thesis fails if Auvelity growth slows, the Alzheimer agitation launch underwhelms, SG&A stays too high for cash-flow positivity, pipeline programs disappoint, financing dilutes holders, or the sales multiple compresses before profits arrive.
Management has converted a CNS development story into a multi-product commercial company. The next test is allocating capital across sales force expansion, late-stage trials, and balance-sheet risk while still guiding toward cash-flow positivity on the current plan.
CNS disorders remain large, under-served markets with durable demand for better oral options. The opportunity is long-term, but pricing scrutiny, competitive launches, and clinical failure rates keep the industry high-risk.
AXSM is priced for continued high product growth and successful pipeline conversion. Margin of safety is limited if investors require profitability sooner, but improves if Auvelity Alzheimer agitation and pipeline milestones expand durable revenue without heavy dilution.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| AXSM price | $233.80 recent public close near July 10 to July 11, 2026 | MarketWatch and ChartMill technical snapshot | July 12, 2026 |
| Market capitalization | $12.03 billion, verified as $233.80 x 51.46 million shares | financial_rigor.py market cap verification | July 12, 2026 |
| Shares outstanding | 51.42 million at March 31, 2026 company report; 51.46 million used in market data snapshots | Axsome Q1 2026 release and Yahoo key statistics cross-check | July 12, 2026 |
| FY2025 total net product revenue | $638.5 million, up 66% year over year | Axsome FY2025 earnings release coverage | July 12, 2026 |
| FY2025 product mix | Auvelity $507.1M, Sunosi $124.8M, Symbravo $6.6M | Axsome FY2025 product sales disclosures | July 12, 2026 |
| FY2025 net loss and EPS | $183.2 million net loss, or $(3.68) per share | Axsome FY2025 earnings release | July 12, 2026 |
| Q1 2026 total net product revenue | $191.2 million, up 57% year over year | Axsome Q1 2026 earnings release | July 12, 2026 |
| Q1 2026 product mix | Auvelity $153.2M, Sunosi $33.9M, Symbravo $4.1M | Axsome Q1 2026 earnings release | July 12, 2026 |
| Q1 2026 net loss, cash, and debt | Net loss $64.5 million; cash $305.1 million; short-term borrowings $70.0 million plus long-term loan payable about $117.9 million | Axsome Q1 2026 balance sheet and income statement | July 12, 2026 |
| Technical support and resistance | Support $232.02 to $233.79 and $216.47; resistance near $255.18; SMA50 $234.47; SMA200 $176.66 | ChartMill technical analysis | July 12, 2026 |
This AXSM AI stock analysis page is an informational research tool only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are scenarios based on available data as of July 12, 2026 and can be wrong if financial results, clinical data, regulation, competition, interest rates, or market sentiment change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
